CyFlow™ CD13 PE-Cy7

Alternative Name:	APN , gp150
Antibody:	Yes
Antigen:	CD13
Clonality:	monoclonal
Clone:	WM15
Emission Maximum:	785 nm
Excitation Maximum:	496 nm, 565 nm
Field of Interest:	Immunophenotyping
Format/Fluorochrome:	PE-Cy7
Isotype:	IgG1
Laser:	Blue , Green, Yellow
Regulatory Status:	ASR
Source Species:	Mouse
Target Species:	Human
Product number:	AR629883

Analytical and performance characteristics are not established

$495.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA III—WS Code M 213 HLDA IV—WS Code M 44 HLDA IV—WS Code M 209 HLDA V—WS... more

Close menu

CyFlow™ CD13 PE-Cy7

HLDA Workshop	HLDA III—WS Code M 213 HLDA IV—WS Code M 44 HLDA IV—WS Code M 209 HLDA V—WS Code M MA191
Concentration Unit	µg/mL
Concentration	80
Volume	1.0 mL
Immunogen	Human Acute Myelogenous Leukemia (AML) cells
Antigen Distribution	CD13 (APN, gp150) is a 150 kDa type II transmembrane zinc-binding ectopeptidase expressed on various cell types. This metalloprotease preferentially catalyzes removal of neutral amino acids from small peptides.
Usage	The reagent may have application in various test methodologies, including Flow Cytometry. Vial has sufficient volume for 100 tests, if used at 10 μL·/·test. User has responsibility for determining reagent quantity per test for any ASR reagent.
Storage Buffer	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

Specific References

| Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Berndt MC, Musgrove E: Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells. Pathology. 1985·Jul; 17(3):392‑9. <·PMID:·3865147·> | Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Musgrove E: Myeloid progenitor surface antigen identified by monoclonal antibody. Br·J·Haematol. 1985·Sep; 61(1):44136. <·PMID:·4052321·> | McMichael AJ, Beverley PCL, Cobbold S, et al (Eds): Leucocyte Typing III, White Cell Differentiation Antigens. Oxford·University·Press,·Oxford. 1987; 1‑1050. <·NLM·ID:·8913266·> | Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·> | Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·> | Favaloro EJ, Browning T, Facey D: CD13 (GP150: aminopeptidase‑N): predominant functional activity in blood is localized to plasma and is not cell‑surface associated. Exp·Hematol. 1993·Dec; 21(13):1695‑701. <·PMID:·7902291·> | Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M: Clinical significance of aminopeptidase N in non‑small cell lung cancer. Clin·Cancer·Res. 2006·Jul·1; 12(13):3971‑8. <·PMID:·16818694·> | Petrovic N, Schacke W, Gahagan JR, O'Conor CA, Winnicka B, Conway RE, Mina-Osorio P, Shapiro LH: CD13/APN regulates endothelial invasion and filopodia formation. Blood. 2007·Jul·1; 110(1):142‑50. <·PMID:·17363739·> | Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F: Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC·Cancer. 2007·Jul·27; 7:140. <·PMID:·17655775·> | McCormack E, Mujić M, Osdal T, Bruserud Ø , Gjertsen BT: Multiplexed mAbs: a new strategy in preclinical time‑domain imaging of acute myeloid leukemia. Blood. 2013·Feb·14; 121(7):e34‑42. <·PMID:·23243270·>

Close menu

Technical Data Sheet

CyFlow CD13 PE-Cy7 (WM15) AR629883 TDS ASR EN.pdf

Safety Data Sheet

CyFlow Monoclonal Antibodies_SDS_US_EN.pdf

Close menu

Technical Support - (888) 879-7639, option 1
Customer Service - (888) 879-7639, option 5
Sales - cytometry@sysmex.com